Allied Corp. (ALID) sourced the active ingredients to produce Psilonex™, its formulation of psilocybin, functional mushrooms, and vitamins. It will be used in conjunction with a daily dose of CBD in an upcoming clinical trial on depression, anxiety, and PTSD.
ALLIED CORP LAUNCHES “ALLIED INSIDE™” APPROACH FOR WHOLESALE PRODUCT OFFERING WITH TRADEMARK FILING
Kelowna, BC, Canada – November 02, 2021 Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID) is pleased to announce the launch of the Allied Inside™ approach to wholesale cannabis product offering.
On October 30, 2021 Allied filed trademark for protection of the words and logo mark that demarks the Allied Inside™ product.
About Allied Inside™: CLICK TO VIEW ALLIED INSIDE
The intention of Allied Inside™ is to give consumers an identifiable brand that is known for its quality and consistency. This represents a standardization of what we believe to fill a gap in the international wholesale marketplace. All Allied Inside™ product is produced at the Colombian Campus and is quarantined until it is reviewed against European Pharmacopeia standards before being released for sale.
We believe that the Allied Inside™ model enables large scale sales and distribution companies (the “partner”) to sell the Allied produced product under their own brand into their markets. By engaging in the Allied Inside™ supply chain, we believe that this enables the international partner in the following ways:
- The international partner avoids the capex needed to build out the production center in their country. Allied provides the product on a weekly schedule and to the specifications that the international partner orders.
- Zero on-going production opex costs as Allied handles this.
- Zero on-going operational management and human resource management risk as Allied handles all of this.
- Zero production expertise needed as Allied handles this.
- Pricing structure that de-risks the sales cycle and allows you to bring your brand to your sales and distribution. Allied offers a pricing structure that involves a nominal up-front payment followed by payment terms on the remaining amount so that the international partner can sell through into their market.
Price point that delivers product to you at approx. half of the cost than it would cost you to produce.
The product is provided to the international partner every week on time, within budget and adhering to the partner-market quality assurance standards.
Enables the international partner to be faster to market as there is no physical production infrastructure required in the climate where the partner is located. Product is provided as Colombian produced. We believe that this enables first market mover advantage.
Here is a link to the Allied Inside trademarked logo: LINK HERE
This mark will be intended to be represented on the back of each package of branded cannabis that is sold into the international marketplace. The supply channel partner will represent and sell their product under their brand, with the Allied Inside™ mark appearing somewhere on the packaging.
Allied will be only providing cannabis flower after the Colombian government allows it and will provide supply only to countries where it is legal to sell into (for example, the United States currently only allows for THC levels to be less than 0.3%).
“The Allied Inside™ mark is an exciting way to show the international consumers that the product under the various brands has been produced with the Allied Corp high quality standards. With several supply contracts signed for the 2022 calendar year, we are ready to start shipping when Colombia allows. Allied harvests on a weekly basis and by nature of this we believe that we will be able to provide rolling supply that is harvested fresh every week. In addition to this, we are offering attractive terms to approved off take partners to offer what we believe to be a de-risked pricing structure and sales cycle.” said Mr. Calum Hughes, CEO and Chairman of Allied Corp.
About Allied Corp. – https://allied.health/
Allied Corp. is an international cannabis company with its main production center in Colombia and is one of the few companies that has exported from Colombia internationally. In preparation for the possible legalization of cannabis by the US Federal Government, Allied also has the option to purchase a US cannabis license in the US (Nevada) exercisable if such were to happen. In addition to this, Allied has three CBD-brands to market with products selling in the United States. Lastly, Allied has both Cannabinoid and psilocybin products in the pharmaceutical development track seeking pharma drug indications for depression, anxiety and PTSD.
This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or the United States ( “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and the introduction of TACTICAL RELIEF™ branded products.
There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company’s continuous disclosure including its Management’s Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company’s profile at www.sec.gov.
Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
Allied Corp. (ALID) has a new approach for treating depression, anxiety and PTSD.
The Kelowna-based company developed a proprietary formulation called Psilonex RX that combines psilocybin extract with functional mushroom extracts and a blend of vitamins.
Allied Corp. aims to treat patients by prescribing a dose of Psilonex RX followed by a daily dose of its CBD product, Psilonex Daily.
The company just began manufacturing Psilonex RX under an agreement with HAVN Life Sciences (HAVN).